CN106810532B - A kind of amine alkoxy thioxanthene ketone class compound, preparation method and use - Google Patents
A kind of amine alkoxy thioxanthene ketone class compound, preparation method and use Download PDFInfo
- Publication number
- CN106810532B CN106810532B CN201611181250.5A CN201611181250A CN106810532B CN 106810532 B CN106810532 B CN 106810532B CN 201611181250 A CN201611181250 A CN 201611181250A CN 106810532 B CN106810532 B CN 106810532B
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- pharmaceutically acceptable
- thioxanthene ketone
- ketone class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
- C07D335/12—Thioxanthenes
- C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
- C07D335/16—Oxygen atoms, e.g. thioxanthones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of novel amine alkoxy thioxanthene ketone class compound (I) and its pharmaceutically acceptable salt, preparation method, pharmaceutical composition and the purposes in preparation treatment and/or prevention nervus retrogression related disease drug, the including but not limited to neurodegenerative diseases such as vascular dementia, Alzheimer's disease, parkinsonism, Huntingdon disease, HIV related dementia disorders, multiple sclerosis, progressive lateral sclerosis of spinal cord, neuropathic pain, glaucoma;
Description
Technical field
The invention belongs to field of medicinal chemistry, are related to a kind of novel amine alkoxy thioxanthene ketone class compound (I) and its pharmacy
It goes up acceptable salt, preparation method, pharmaceutical composition and nervus retrogression related disease drug is treated and/or prevented in preparation
In purposes, including but not limited to vascular dementia, Alzheimer's disease, parkinsonism, Huntingdon disease, HIV related dementias
The neurodegenerative diseases such as disease, multiple sclerosis, progressive lateral sclerosis of spinal cord, neuropathic pain, glaucoma.
Background technique
Alzheimer's disease (Alzheimer ' s disease, AD, senile dementia) is one kind with progressive cognitive disorder
With the central nervous system degenerative disease based on memory damage, disease incidence becomes in trend is risen year by year and is only second to the heart
The high incidence disease of angiosis and cancer, having gone up in developed countries such as America and Europes is the 4th of the cause of death.According to world health
Organisation Report, global over-65s old man have 10% dysnoesia, and wherein half occurs dull-witted, fall ill within 85 years old or more
Rate nearly 50%.The AD patient numbers about 600-700 ten thousand in China, disease incidence are more than 5%.With adding for population in the world aging process
Fastly, disease incidence is in obvious ascendant trend, is announced according to Alzheimer's Disease International in September, 2016
" World Alzheimer Report 2016 " report in point out, AD is good for the maximum that faces of the coming few decades whole world is become
Health challenge, to the year two thousand thirty, patient numbers will rise to 76,000,000 by 47,000,000 in 2015, and to the year two thousand fifty, this numerical value will reach
To surprising 1.31 hundred million.Due to AD clinical manifestation be memory capability, capacity of orientation, thinking and judgement decline and it is daily
Viability reduces, or even abnormal Behavioral and psychological symptom occur etc., while it being also accompanied by significant depressive symptom, make patient care
Difficulty is larger, brings heavy burden to society and family.The drug that approved is used to treat light/moderate AD at present has acetylcholine
Esterase (AChE) inhibitor, and for severe AD treatmentNMethyl-DAspartic acid (NMDA) receptor antagonist, but it is clinical
Using show these drugs can by improve patient's body levels of acetylcholine or inhibit excitatory amino acid exitotoxicity
Alleviate AD symptom, but not can effectively prevent or reverse the course of disease, but also can cause hallucinations, misunderstanding, dizziness, headache, evil
The serious toxic side effect such as the heart, hepatotoxicity, loss of appetite and stool frequency, thus long-term efficacy is not satisfactory.Therefore, clinical
On there is an urgent need to research and develop the AD therapeutic agent with novel mechanism of action.
AD belongs to disease caused by many factors, and pathogenesis is complicated, does not illustrate its pathogenesis completely also so far, but study
Show patient's intracerebral levels of acetylcholine decline,βThe excessive generation and deposition, metal ion metabolism of amyloid protein are disorderly
Disorderly, Ca2+Dysequilibrium,tauNeurofibrillary tangles caused by protein hyperphosphorylation, monoamine oxidase B (MAO-B) activity increase
By force, glutamate receptor activity is excessively high, oxidative stress generates a large amount of active oxygens (ROS) and free radical and Neuroinflammation etc. are more
Kind factor is played an important role in the pathogenic process of AD.In addition, current research finds that there is also significant by most of AD patients
Depressive symptom, depression can increase intracerebralβThe deposition of amyloid protein simultaneously aggravates its cognition dysfunction.For above-mentioned morbidity
Factor, researcher is using traditional " one target of a medicine " drug design strategies, it was found that largely to a certain target spot have high activity and
Highly selective drug, such as: anticholinesterase andNMethyl-DAspartate receptor agonist etc., but these drugs are deposited
The problems such as action target spot is single, clinical use toxic side effect is more, not good enough to the long-term efficacy of AD patient.
In recent years, with constantly illustrating to AD pathogenesis, it is found that the occurrence and development of AD have multimachine system, multifactor
It is the characteristics of effect, again interrelated between different mechanisms to influence each other, constitute complicated network during AD occurrence and development
Regulator control system.Based on the above results, researcher proposes " multiple target point targeted drug " (Multitarget-directed
Ligands, MTDLs) strategy researches and develops anti-neurodegenerative disease drug.So-called " multiple target point drug " refers to that single chemistry is real
Body acts on multiple target spots in disease network simultaneously, can produce synergistic effect to the effect of each target spot, is greater than gross effect each
Single-action the sum of is answered, and such medicine is also referred to as " Multifunctional " or " Multipotential " drug.Multiple target point drug and more
Medicine use in conjunction and the main distinction of compound medicine are: can reduce dosage, improve therapeutic effect, avoid between drug
Interaction and thus bring toxic side effect, uniform pharmacokinetic properties, be easy to use etc..It designs and finds have simultaneously
Have and inhibits monoamine oxidase A and B, anti-oxidation stress, resistsβExcessive generation and the deposition, selective complexation maincenter of amyloid protein
Metal ion (especially Cu in tissue2+And Fe2+), and the multiple target point AD medicine that multiple biological activities intensity is more balanced
Object is current research hotspot.Therefore, research and development have novel chemical structure, novel mechanism of action, and have multiple target point (or
It is multi-functional) effect, less toxic side effect anti-neurodegenerative disease therapeutic agent not only conform with the urgent of social senilization's process
Demand, and there are good market prospects.
Summary of the invention
Present invention aims at open a kind of novel amine alkoxy thioxanthene ketone class compounds (I) and its pharmaceutically acceptable
Salt;
Another object of the present invention is to disclose such amine alkoxy thioxanthene ketone class compound (I) and its pharmaceutically acceptable
The preparation method of salt;
Another object of the present invention is to open comprising such amine alkoxy thioxanthene ketone class compound (I) and its pharmaceutically may be used
The pharmaceutical composition of the salt of receiving;
Still a further object of the present invention is to disclose such amine alkoxy thioxanthene ketone class compound (I) and its pharmaceutically acceptable
Salt has multiple target effect, can be used for preparing the purposes in the drug for the treatment of and/or prevention nervus retrogression related disease, including
But it is not limited to vascular dementia, Alzheimer's disease, parkinsonism, Huntingdon disease, HIV related dementia disorders, multiple sclerosis
The neurodegenerative diseases such as disease, progressive lateral sclerosis of spinal cord, neuropathic pain, glaucoma.
The general formula of the chemical structure of amine alkoxy thioxanthene ketone class compound (I) disclosed in this invention are as follows:
In formula: R expression-(CH2)n-NR1R2, n expression 2-12, R1Indicate H, C1~C12Alkyl;R2Indicate C1~C12Alkyl, benzyl
Base or substituted benzyl;NR1R2May also indicate that nafoxidine base, morpholinyl, piperidyl, 4- by C1~C12Piperidines replaced alkyl
Base, the 4- piperidyls replaced benzyl or substituted benzyl, piperazinyl, 4- by C1~C12Piperazinyl replaced alkyl, 4-
Position piperazinyl replaced benzyl or substituted benzyl;R may also indicate that, m expression 1-10, R3Expression H,
C1~C12Alkyl, benzyl or substituted benzyl;Above-mentioned term " substituted benzyl " refer to by phenyl ring by 1-4 groups selected from the group below
Replaced benzyl: F, Cl, Br, I, C1-4Alkyl, C1-4Alkoxy, trifluoromethyl, trifluoromethoxy, dimethylamino, nitro, cyanogen
Base, these substituent groups can be in any possible positions of phenyl ring.
Amine alkoxy thioxanthene ketone class compound (I) proposed by the invention can be prepared by the following method to obtain:
(1) as R expression-(CH2)n-NR1R2, when n indicates 2-12:
In formula: X indicates Cl, Br, I;R1、R2, the definition of n it is identical as general formula of the chemical structure (I);
Step a): with 1,3- dihydroxy thioxanthones (1) be starting material, under solvent and alkaline condition with Dihaloalkyl
Object (2) reaction is closed, corresponding 1- hydroxyl -3- oxyalkyl halogen compound (3) is generated;
Step b): the intermediate 3 obtained by step a) reacts in a solvent with organic amine compound (4), obtains corresponding amine
Alkoxy thioxanthene ketone class compound (I);
Its specific preparation method is described as follows:
In the step a), alkali used is reacted are as follows: alkali metal hydroxide, alkaline earth metal hydroxide, alkali metal carbonic acid
Salt, alkaline earth metal carbonate, alkali metal hydrogencarbonate, alkali metal bicarbonates, C1-8The alkali metal salt of alcohol, trimethylamine class
Or quaternary ammonium bases (such as: triethylamine, tri-n-butylamine, trioctylamine, pyridine,NMethyl morpholine,NMethyl piperidine, triethylene diamine, four fourths
Base ammonium hydroxide), preferred alkali are as follows: potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, triethylamine, pyridine or sodium methoxide;Reaction
Solvent for use are as follows: ether, tetrahydrofuran,N,NDimethylformamide, dimethyl sulfoxide, methylene chloride, chloroform, C3-8Aliphatic ketone,
Benzene, toluene, acetonitrile or C5-8Alkane, preferred solvent are as follows:N,NDimethylformamide, acetone, acetonitrile, tetrahydrofuran or toluene;1,
3- dihydroxy thioxanthones (1): Dihaloalkyl compound (2): the molar feed ratio of alkali is 1.0:1.0 ~ 10.0:1.0 ~ 10.0, excellent
Selecting molar feed ratio is 1.0:1.0 ~ 5.0:1.0 ~ 5.0;Reaction temperature is room temperature ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120
℃;Reaction time is 1 ~ 72 hour, and preferred reaction time is 2 ~ 24 hours;
In the step b), react solvent for use are as follows: ether, tetrahydrofuran,N,NDimethylformamide, dimethyl are sub-
Sulfone, methylene chloride, chloroform, C3-8Aliphatic ketone, benzene, toluene, acetonitrile, C1-8Alcohol or C5-8Alkane, preferred solvent are as follows:N,NDimethyl
Formamide, acetone, acetonitrile, tetrahydrofuran, ethyl alcohol or toluene;Intermediate (3): the molar feed ratio of organic amine compound (4)
For 1.0:1.0 ~ 10.0, preferably molar feed ratio is 1.0:1.0 ~ 5.0;Reaction temperature is room temperature ~ 150 DEG C, preferable reaction temperature
For room temperature ~ 120 DEG C;Reaction time is 1 ~ 72 hour, and preferred reaction time is 2 ~ 24 hours.
(2) when R is indicated, when m indicates 1-10:
In formula: X indicates Cl, Br, I;R3, the definition of m it is identical as general formula of the chemical structure (I);
With 1,3- dihydroxy thioxanthones (1) be starting material, under solvent and alkaline condition with 1- substitution -4- alkylhalide group piperazine
Pyridine (5) reaction, obtains corresponding amine alkoxy thioxanthene ketone class compound (I);
Its specific preparation method is described as follows:
React alkali used are as follows: alkali metal hydroxide, alkaline earth metal hydroxide, alkali carbonate, alkaline-earth metal carbon
Hydrochlorate, alkali metal hydrogencarbonate, alkali metal bicarbonates, trimethylamine class or quaternary ammonium bases are (such as: triethylamine, tri-n-butylamine, three
Octylame, pyridine,NMethyl morpholine,NMethyl piperidine, triethylene diamine, tetrabutylammonium hydroxide) or C1-8The alkali metal salt of alcohol,
It is preferred that alkali are as follows: potassium hydroxide, sodium hydroxide, potassium carbonate, triethylamine, pyridine or sodium methoxide;React solvent for use are as follows: ether, four
Hydrogen furans,N,NDimethylformamide, dimethyl sulfoxide, methylene chloride, chloroform, C3-8Aliphatic ketone, benzene, toluene, acetonitrile or C5-8
Alkane, preferred solvent are as follows:N,NDimethylformamide, acetone, acetonitrile, tetrahydrofuran or toluene;1,3- dihydroxy thioxanthones
(1): 1- substitution -4- alkyl halide phenylpiperidines (5): the molar feed ratio of alkali is 1.0:1.0 ~ 10.0:1.0 ~ 10.0, preferably mole is fed intake
Than for 1.0:1.0 ~ 3.0:1.0 ~ 5.0;Reaction temperature is room temperature ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120 DEG C;When reaction
Between be 1 ~ 72 hour, preferred reaction time be 2 ~ 24 hours.
Contain amino in amine alkoxy thioxanthene ketone class compound (I) molecule of gained according to the method described above, which is in alkali
Property, its pharmaceutically acceptable salt, the acid can be made by pharmaceutically conventional salifying method with any suitable acid
Are as follows: hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, C1-6Aliphatic carboxylic acid (such as: formic acid, acetic acid, propionic acid), oxalic acid, benzoic acid, water
Poplar acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, malic acid, lipoic acid, C1-6Alkyl sulfonic acid is (such as: methyl sulphur
Acid, ethylsulfonic acid etc.), camphorsulfonic acid, benzene sulfonic acid or p-methyl benzenesulfonic acid.
Pharmaceutical composition disclosed in this invention includes one or more amine alkoxy thioxanthene ketone class of therapeutically effective amount
Object (I) or its pharmaceutically acceptable salt are closed, which can be further containing one or more pharmaceutically acceptable
Carrier or excipient." therapeutically effective amount ", which refers to, causes researcher or targeted tissue, system or the life of animal of doctor
The amount of the drug or medicament of object or medicine reaction;" composition " refers to by mixing more than one substances or component
Product;" pharmaceutically acceptable carrier " refers to pharmaceutically acceptable substance, composition or carrier, such as: liquid or
Solid-filling agent, diluent, excipient, solvent or packing substance, they carry or transport certain chemical substance.The present invention is mentioned
Its ideal ratio of the pharmaceutical composition of confession is that amine alkoxy thioxanthene ketone class compound (I) or its pharmaceutically acceptable salt are made
Total weight is accounted for than 2%~99.5% for active constituent, and rest part is to account for total weight than 98% or less.
Amine alkoxy thioxanthene ketone class compound (I) disclosed in this invention and its pharmaceutically acceptable salt have carried out as follows
Bioactivity screening.
(1) inhibitory activity of the amine alkoxy thioxanthene ketone class compound (I) to monoamine oxidase A and B
Recombined human MAO-A is made into 12.5 μ g/mL sample liquids with 7.4 kaliumphosphate buffer of pH of 100 mM, by MAO-B
It is made into 75 μ g/mL sample liquids.20 μ L of testing compound solution, 80 μ L of monoamine oxidase are added into 96 orifice plate of black, mixes
Even, 37 °C are incubated for 15 min in the place of being protected from light, and 200 μM of Amplex Red reagents, 2U/mL horseradish peroxidase, 2 mM are added
Uteramin (inhibiting MAO-A) or 2 mM benzene methanamines (inhibiting MAO-B) initiation reaction, 37 °C of 20 min of incubation, in more function
In energy microplate reader, to fix 545 nm of excitation wavelength, fluorescent emission intensity at 590 nm is surveyed, MAO- is replaced with kaliumphosphate buffer
A or MAO-B is blank;The inhibiting rate calculation formula of compound inhibition monoamine oxidase are as follows: 100- (IFi)/(IFc) * 100, formula
In, IFiAnd IFcRespectively there is the difference of the fluorescence intensity and blank fluorescence intensity under inhibitor and no inhibitor.Each compound
3 multiple holes of measurement every time, every group of experiment are independent in triplicate.Five to six concentration for selecting compound, measure its enzyme inhibition rate,
And with the inhibiting rate linear regression of the negative logarithm of the compound molar concentration and enzyme, molar concentration when acquiring 50% inhibiting rate is i.e.
For the IC of the compound50.Measurement result shows the amine alkoxy thioxanthene ketone class compound (I) disclosed in the embodiment of the present invention
The effect of significantly inhibiting is all had to MAO-A and MAO-B, wherein the IC inhibited to MAO-A50It is 0.3 μM ~ 10.0 μM, to MAO-
The IC that B inhibits50It is 0.1 μM ~ 10.0 μM.
(2) amine alkoxy thioxanthene ketone class compound (I) is to Aβ 1-42The inhibitory activity of self assemble
Reference literature (Qiang, X.M.et al.Eur. J Med. Chem.2014,76,314-331) reported
Method be measured, it may be assumed that pretreated Aβ 1-42It is made into stock solution with DMSO, using preceding dilute with the PBS buffer solution of pH7.4
It releases to 50 μM;Untested compound is made into 2.5 mM stock solutions with DMSO, is diluted to accordingly using preceding with the PBS buffer solution of pH7.4
Concentration takes the A of 20 μ Lβ 1-42The A of the testing compound solution of+20 μ L of solution, 20 μ Lβ 1-42The PBS buffer solution of+20 μ L of solution (contains
2%DMSO) in 96 orifice plates, 37 °C are incubated for for 24 hours, and the glycine-NaOH for the 50mM that 160 μ L contain 5 μM of thioflavine Ts is then added
Buffer (pH=8.5) is surveyed under 446 nm excitation wavelengths and 490 nm launch wavelengths with multi-function microplate reader immediately after shaking 5s
Determine fluorescent value;Aβ 1-42The fluorescent value of+untested compound is denoted as IFi, Aβ 1-42The fluorescent value of+PBS buffer solution is denoted as IFc, contain only
The fluorescent value of PBS buffer solution is denoted as IF0, compound inhibition Aβ 1-42The inhibiting rate of self assemble are as follows: 100- (IFi-IF0)/(IFc-
IF0)*100;Five to six concentration for selecting compound, measure its inhibiting rate, each each concentration repetition measurement of compound three times, with
Curcumin is positive control.Measurement result shows the amine alkoxy thioxanthene ketone class compound (I) disclosed in the embodiment of the present invention
To Aβ 1-42Self assemble all has remarkable inhibiting activity, to A under 25.0 μM of concentrationβ 1-42The inhibiting rate of self assemble is all larger than
40.0%;Control drug used: 1,3- dihydroxy thioxanthones (1) and curcumin are under same concentrations to Aβ 1-42The suppression of self assemble
Rate processed is respectively 9.5% and 36.2%.
(3) measurement of amine alkoxy thioxanthene ketone class compound (I) and complexing of metal ion effect
CuCl is dissolved with methanol2·2H2O、ZnCl2、FeSO4·7H2O、AlCl3And untested compound, it is made into 75 μm of ol/L
Solution, 100 μ L testing compound solutions and 100 μ L metal ion solutions are added into 96 orifice plates, mix, be stored at room temperature 30
Min records ultraviolet absorption curve of the mixture within the scope of 200-600 nm on multi-function microplate reader, and to be measured with 100 μ L
Compound solution and 100 μ L methyl alcohol mixed liquors are control, observe the maximum absorption band of metal ion and untested compound mixed liquor
Red Shift Phenomena and maximum absorption band intensity.Measurement result shows the amine alkoxy thioxanthene disclosed in the embodiment of the present invention
Ketone compounds (I) are shown to Cu2+And Fe2+With selective complexation effect, and to Zn2+And Al3+Make almost without complexing
With.
(4) amine alkoxy thioxanthene ketone class compound (I) is to Cu2+The A of inductionβ 1-42The inhibitory activity of aggregation
By CuCl275 μM of solution are made into HEPES buffer solution, with HEPES buffer solution by compound stock solution (2.5 mM)
With 200 μM of Aβ 1-42Stock solution is diluted to 75 μM, takes 20 μ L Cu respectively2++ 20 μ L A of solutionβ 1-42+ 20 μ L to be measuredization of solution
Polymer solution, 20 μ L Cu2++ 20 μ L A of solutionβ 1-42+ 20 μ L HEPES buffer solution of solution and 60 μ L HEPES buffer solutions are in 96
It in orifice plate, mixes, then the glycine-NaOH buffer for the 50mM that 190 μ L contain 5 μM of thioflavine Ts is added in 37 °C of 24 h of incubation
(pH=8.5) measure fluorescence under 446nm excitation wavelength and 490nm launch wavelength with multi-function microplate reader immediately after shaking 5s
Value;Cu2++Aβ 1-42The fluorescent value of+untested compound is recorded as IFi, Cu2++Aβ 1-42The fluorescent value of+HEPES buffer solution is recorded as
IFc, the fluorescent value for containing only HEPES buffer solution is recorded as IF0, compound is to Cu2+The A of inductionβ 1-42The inhibiting rate of aggregation are as follows:
100-(IFi-IF0)/(IFc-IF0)*100.Each each three multiple holes of concentration mensuration of compound, using curcumin as positive control.
Measurement result shows that the amine alkoxy thioxanthene ketone class compound (I) disclosed in the embodiment of the present invention is right under 25.0 μM of concentration
Cu2+The A of inductionβ 1-42The inhibiting rate of aggregation is all larger than 75.0%;And inhibiting rate of the curcumin under same concentrations is 62.1%, 1,
Inhibiting rate of the 3- dihydroxy thioxanthones (1) under same concentrations is only 31.4%.
(5) antioxidant activity (ORAC-FL method) of amine alkoxy thioxanthene ketone class compound (I)
Reference literature (Qiang, X.M.et al.Eur. J Med. Chem.2014,76,314-331) reported
Method be measured, it may be assumed that 6- hydroxyl -2,5,7,8- tetramethyl primary colours alkane -2- carboxylic acids (Trolox) use pH7.4 PBS buffer solution
It is made into the solution of 10-80 μm of ol/L, fluorescein (fluorescein) is made into 250 nmol/L's with the PBS buffer solution of pH7.4
Solution, 2,2 '-azo diisobutyl amidine dihydrochlorides (AAPH) are made into 40 mmol/L's with the PBS buffer solution of pH7.4 using preceding
Solution.The compound solution and luciferin solution of 50-10 μm of ol/L are added into 96 orifice plates, mixes, 37 °C of incubation 15min add
Enter AAPH solution, make every 200 μ L of hole total volume, mixes, be immediately placed in multi-function microplate reader, in 485 nm excitation wavelengths
With 90 min of METHOD FOR CONTINUOUS DETERMINATION under 535 nm launch wavelengths.Area AUC under fluorescence decay curve is calculated, wherein with 1-8 μm of ol/L
'sTroloxAs standard, sample to be tested is not added as blank, the antioxidant activity results expression of compound isTroloxWork as
Amount, its calculation formula is: [(AUC Sample-AUC blank)/(AUCTrolox-AUC blank)]´
[(concentration of Trolox/ concentration of sample)], each compound measures 3 again every time
Hole, every group of experiment are independent in triplicate.Measurement result shows the amine alkoxy thioxanthene ketone class disclosed in the embodiment of the present invention
Close object (I) antioxidant activity beTrolox0.5-2.0 times, illustrate such compound have strong anti-oxidative activity.
Specific embodiment
The present invention can be further described by the following examples, however, the scope of the present invention is not limited to
Following embodiments.One of skill in the art, can be right it is understood that under the premise of without departing substantially from the spirit and scope of the present invention
The present invention carries out various change and modification.
Embodiment 1
R expression-(CH2)n-NR1R2, when n indicates 2-12, method is led in the preparation of amine alkoxy thioxanthene ketone class compound (I)
(1) 2.0 mmol of 1,3- dihydroxy thioxanthones, 30 ml acetonitriles, 7.0 mmol Carbon Dioxides are added in reaction flask
(2) 7.0 mmol of potassium and dibromo alkyl compound, temperature rising reflux be stirred to react 3.0~12.0 hours (reaction process TLC with
Track);After reaction, it filters while hot, a small amount of acetonitrile washs filter cake, and solvent and excessive dibromo alkyl chemical combination is evaporated off in filtrate decompression
Object, residue are purified by silica gel column chromatography (eluent: petroleum ether-ethyl acetate=30:1 v/v), obtain 1- hydroxyl -3- oxyalkyl
Halogen compound (3), yield 76.2%-88.0%;
Above-mentioned 1- hydroxyl -3- oxyalkyl halogen compound (3) full dose is dissolved in 30 ml ethyl alcohol, it is organic that 6.0 mmol are added
Aminated compounds (4), temperature rising reflux are stirred to react 6.0~16.0 hours (reaction process is tracked with TLC);After reaction, subtract
Pressure solvent is evaporated off, 50 ml methylene chloride are added in residue, successively with 20 ml, 5% sodium hydrate aqueous solution and 20 ml go from
Sub- water washing, organic layer filter after being dried over anhydrous sodium sulfate, evaporating solvent under reduced pressure, residue through column chromatographic purifying (eluent:
Petroleum ether-ethyl acetate=30:1 v/v), obtain corresponding amine alkoxy thioxanthene ketone class compound (I), yield 72.0%-90.6%,
Its chemical structure passes through1H-NMR、13The purity of C-NMR and ESI-MS confirmation, gained object is all larger than through HPLC measurement
97.0%.The object structure being prepared using above-mentioned logical method is as follows:
2 R of embodiment is indicated, when m indicates 1-10, amine alkoxy thioxanthene ketone class compound (I)
Prepare logical method
(1) 2.0 mmol of 1,3- dihydroxy thioxanthones, 30 ml acetonitriles, 3.0 mmol Carbon Dioxides are added in reaction flask
Potassium and 2.5 mmol 1- substitution -4- alkyl halide phenylpiperidines (5), temperature rising reflux is stirred to react 6.0~16.0 hours, and (reaction process is used
TLC tracking);After reaction, it filters while hot, a small amount of acetonitrile washs filter cake, and solvent is evaporated off in filtrate decompression, and residue is chromatographed through column
It purifies (eluent: petroleum ether-ethyl acetate=30:1 v/v), obtains corresponding amine alkoxy thioxanthene ketone class compound (I), yield
70.8%-86.0%, chemical structure pass through1H-NMR、13C-NMR and ESI-MS confirmation, the purity of gained object are surveyed through HPLC
Surely it is all larger than 97.0%.The object structure being prepared using above-mentioned logical method is as follows:
3 amine alkoxy thioxanthene ketone class compound (I) of embodiment and acid are prepared at salt leads to method
The amine alkoxy thioxanthene ketone class compound (I) 2.0 of -2 gained in accordance with the above-mentioned embodiment 1 is added in reaction flask
50 ml of mmol and acetone, is stirring evenly and then adding into that 6.0 mmol are sour accordingly, and temperature rising reflux is stirred to react 20 minutes, reaction knot
It is cooled to room temperature after beam, evaporating solvent under reduced pressure, residue acetone recrystallization, filters the solid of precipitation to get amine alkoxy thiophene
The salt of xanthones compound (I), chemical structure warp1H NMR and ESI-MS confirmation.
Claims (10)
1. a kind of amine alkoxy thioxanthene ketone class compound or its pharmaceutically acceptable salt, it is characterised in that the change of such compound
It is shown to learn general structure such as (I):
In formula: R expression-(CH2)n-NR1R2, n expression 2-12, R1Indicate H, C1~C12Alkyl;R2Indicate C1~C12Alkyl, benzyl or
Substituted benzyl;NR1R2Also illustrate that nafoxidine base, morpholinyl, piperidyl, 4- by C1~C12Piperidyl replaced alkyl, 4-
Position piperidyl replaced benzyl or substituted benzyl, piperazinyl, 4- by C1~C12Piperazinyl replaced alkyl, 4- quilt
Piperazinyl replaced benzyl or substituted benzyl;R is also illustrated that, m expression 1-10, R3Indicate H, C1~C12
Alkyl, benzyl or substituted benzyl;Above-mentioned " substituted benzyl " refers to the benzyl replaced 1-4 groups selected from the group below on phenyl ring
Base: F, Cl, Br, I, C1-4Alkyl, C1-4Alkoxy, trifluoromethyl, trifluoromethoxy, dimethylamino, nitro, cyano, these take
Any possible position of the Dai Jike in phenyl ring.
2. amine alkoxy thioxanthene ketone class compound as described in claim 1 or its pharmaceutically acceptable salt, it is characterised in that
The pharmaceutically acceptable salt is such amine alkoxy thioxanthene ketone class compound and hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphorus
Acid, C1-6Aliphatic carboxylic acid, oxalic acid, benzoic acid, salicylic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, malic acid,
Lipoic acid, C1-6Alkyl sulfonic acid, camphorsulfonic acid, benzene sulfonic acid or p-methyl benzenesulfonic acid salt.
3. the preparation of amine alkoxy thioxanthene ketone class compound or its pharmaceutically acceptable salt as described in claim any one of 1-2
Method, it is characterised in that the compound can be prepared by following two method:
Method one: as R expression-(CH2)n-NR1R2, when n indicates 2-12:
In formula: X indicates Cl, Br, I;R1、R2, the definition of n it is identical as general formula of the chemical structure (I);
Step a): with 1,3- dihydroxy thioxanthones (1) be starting material, under solvent and alkaline condition with Dihaloalkyl compound
(2) it reacts, generates corresponding 1- hydroxyl -3- oxyalkyl halogen compound (3);
Step b): the intermediate 3 obtained by step a) reacts in a solvent with organic amine compound (4), obtains corresponding amine alcoxyl
Base thioxanthene ketone class compound (I);
Method two: when R is indicated, when m indicates 1-10:
In formula: X indicates Cl, Br, I;R3, the definition of m it is identical as general formula of the chemical structure (I);
With 1,3- dihydroxy thioxanthones (1) be starting material, under solvent and alkaline condition with 1- substitution -4- alkyl halide phenylpiperidines
(5) it reacts, obtains corresponding amine alkoxy thioxanthene ketone class compound (I);
Using amino is contained in amine alkoxy thioxanthene ketone class compound (I) molecule of above two method gained, which is in alkali
Property, its pharmaceutically acceptable salt can be made by pharmaceutically conventional salifying method with any suitable acid.
4. the preparation method of amine alkoxy thioxanthene ketone class compound as claimed in claim 3 or its pharmaceutically acceptable salt,
It is characterized in that in the step a) of method one, reacts alkali used are as follows: alkali metal hydroxide, alkaline earth metal hydroxide, alkali metal
Carbonate, alkaline earth metal carbonate, alkali metal hydrogencarbonate, alkali metal bicarbonates, C1-8The alkali metal salt of alcohol, triethylamine,
Tri-n-butylamine, trioctylamine, pyridine,NMethyl morpholine,NMethyl piperidine, triethylene diamine or tetrabutylammonium hydroxide;Used in reaction
Solvent are as follows: ether, tetrahydrofuran,N,NDimethylformamide, dimethyl sulfoxide, methylene chloride, chloroform, C3-8Aliphatic ketone, benzene,
Toluene, acetonitrile or C5-8Alkane;1,3- dihydroxy thioxanthones (1): Dihaloalkyl compound (2): the molar feed ratio of alkali is 1.0:
1.0 ~ 10.0:1.0 ~ 10.0;Reaction temperature is room temperature ~ 150 DEG C;Reaction time is 1 ~ 72 hour.
5. the preparation method of amine alkoxy thioxanthene ketone class compound as claimed in claim 3 or its pharmaceutically acceptable salt,
Be characterized in that in the step b) of method one, react solvent for use are as follows: ether, tetrahydrofuran,N,NDimethylformamide, dimethyl
Sulfoxide, methylene chloride, chloroform, C3-8Aliphatic ketone, benzene, toluene, acetonitrile, C1-8Alcohol or C5-8Alkane;Intermediate (3): organic amine
The molar feed ratio of compound (4) is 1.0:1.0 ~ 10.0;Reaction temperature is room temperature ~ 150 DEG C;Reaction time is 1 ~ 72 hour.
6. the preparation method of amine alkoxy thioxanthene ketone class compound as claimed in claim 3 or its pharmaceutically acceptable salt,
It is characterized in that in method two, reacts alkali used are as follows: alkali metal hydroxide, alkaline earth metal hydroxide, alkali carbonate, alkali
Earth metal carbonate, alkali metal hydrogencarbonate, alkali metal bicarbonates, triethylamine, tri-n-butylamine, trioctylamine, pyridine,NMethyl
Morpholine,NMethyl piperidine, triethylene diamine, tetrabutylammonium hydroxide or C1-8The alkali metal salt of alcohol;React solvent for use are as follows: second
Ether, tetrahydrofuran,N,NDimethylformamide, dimethyl sulfoxide, methylene chloride, chloroform, C3-8Aliphatic ketone, benzene, toluene, acetonitrile
Or C5-8Alkane;1,3- dihydroxy thioxanthones (1): 1- substitution -4- alkyl halide phenylpiperidines (5): the molar feed ratio of alkali be 1.0:1.0 ~
10.0:1.0 ~ 10.0;Reaction temperature is room temperature ~ 150 DEG C;Reaction time is 1 ~ 72 hour.
7. a kind of pharmaceutical composition, it is characterised in that comprising such as the described in any item amine alkoxy thioxanthene ketone class of claim 1-2
Compound or its pharmaceutically acceptable salt.
8. pharmaceutical composition as claimed in claim 7, it is characterised in that the pharmaceutical composition further contains one or more
Pharmaceutically acceptable carrier or excipient.
9. pharmaceutical composition as claimed in claim 7 or 8, it is characterised in that the amine alkoxy thioxanthene ketone class compound or its
Pharmaceutically acceptable salt accounts for total weight than 5%~99.5% as active constituent.
10. as the described in any item amine alkoxy thioxanthene ketone class compounds of claim 1-2 or its pharmaceutically acceptable salt exist
Purposes in preparation treatment and/or prevention nervus retrogression related disease drug, this kind of nervus retrogression related disease are as follows: blood vessel
Property dementia, Alzheimer's disease, parkinsonism, Huntingdon disease, HIV related dementia disorders, multiple sclerosis or progressive ridge
Marrow lateral schlerosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611181250.5A CN106810532B (en) | 2016-12-20 | 2016-12-20 | A kind of amine alkoxy thioxanthene ketone class compound, preparation method and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611181250.5A CN106810532B (en) | 2016-12-20 | 2016-12-20 | A kind of amine alkoxy thioxanthene ketone class compound, preparation method and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106810532A CN106810532A (en) | 2017-06-09 |
CN106810532B true CN106810532B (en) | 2019-03-15 |
Family
ID=59110015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611181250.5A Expired - Fee Related CN106810532B (en) | 2016-12-20 | 2016-12-20 | A kind of amine alkoxy thioxanthene ketone class compound, preparation method and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106810532B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114105943A (en) * | 2020-09-01 | 2022-03-01 | 深圳有为技术控股集团有限公司 | 3-substituted thioxanthone compound, preparation method thereof and application of photopolymerization system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1195752A (en) * | 1967-02-10 | 1970-06-24 | Sterling Drug Inc | Xanthene and Thioxanthene Derivatives |
WO1996036347A1 (en) * | 1995-05-17 | 1996-11-21 | Eli Lilly And Company | Use of leukotriene antagonists for alzheimer's disease |
WO2005077899A2 (en) * | 2004-02-04 | 2005-08-25 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7365193B2 (en) * | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
-
2016
- 2016-12-20 CN CN201611181250.5A patent/CN106810532B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1195752A (en) * | 1967-02-10 | 1970-06-24 | Sterling Drug Inc | Xanthene and Thioxanthene Derivatives |
WO1996036347A1 (en) * | 1995-05-17 | 1996-11-21 | Eli Lilly And Company | Use of leukotriene antagonists for alzheimer's disease |
WO2005077899A2 (en) * | 2004-02-04 | 2005-08-25 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
Also Published As
Publication number | Publication date |
---|---|
CN106810532A (en) | 2017-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106632181B (en) | Aurone Mannich alkaloid compound, preparation method and use | |
CN105481706B (en) | The Hydroxylated Chalcones and Related compound of one class 2, preparation method and use | |
CN105481796B (en) | One class carbamic acid chalcone ester type compound, preparation method and use | |
CN105439876B (en) | 2 hydroxylated chalcone aminated compounds, preparation method and use | |
JP5897566B2 (en) | Cyclic N, N'-diarylthiourea and N, N'-diarylurea-androgen receptor antagonists, anticancer agents, methods for their preparation and uses | |
CN105646417B (en) | A kind of 4 hydroxyl aurone class compounds, preparation method and use | |
WO2017035982A1 (en) | Diazonaphthoquinone compounds, preparation method thereof, and medical applications | |
CN106831799B (en) | Hydroxy styrenes pyridine Mannich alkaloid compound, preparation method and use | |
CN108101780A (en) | A kind of Flurbiprofen chalcone compounds, preparation method and use | |
CN108069942A (en) | Phthalide pyrazolone conjugate, preparation method and use | |
CN109734614A (en) | 3- hydroxylated chalcone Mannich alkaloid compound, preparation method and use | |
CN111170884B (en) | Salicylamide compound, preparation method and application thereof | |
CN109265362A (en) | A kind of 2,5- dihydroxy paraphenylene terephthalamide's amine compound, preparation method and use | |
CN106810532B (en) | A kind of amine alkoxy thioxanthene ketone class compound, preparation method and use | |
CN109761945A (en) | A kind of naringenin-O- alkyl amine compound, preparation method and application | |
CN108586411A (en) | A kind of naringenin carbamate compound, preparation method and application | |
AU2015308438B2 (en) | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | |
CA3125321A1 (en) | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases | |
CN106632191B (en) | Homoisoflavone Mannich alkaloid compound, preparation method and use | |
CN114478451B (en) | 6- (hydroxybenzyloxy) phthalein mannich base compound, preparation method and application thereof | |
CN108727352A (en) | A kind of piperidines alkane carbamyl phthalide analog compound, preparation method and use | |
CN114805263B (en) | 3- (hydroxybenzyl) phthalide compound, preparation method and application thereof | |
CN109665969A (en) | The double Mannich alkaloid compounds of 3- methoxyl group -4-HC, preparation method and use | |
CN110272349B (en) | 2' -hydroxy-3-phenyl propiophenone compound and preparation method and application thereof | |
CN110003034A (en) | A kind of hydroxyl Flurbiprofen Mannich alkaloid compound, preparation method and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190315 Termination date: 20191220 |
|
CF01 | Termination of patent right due to non-payment of annual fee |